Solid Biosciences Inc. reported a net loss of $39.282 million for the first quarter of 2025, an increase from the $24.303 million net loss in the same period last year. The company's total operating expenses increased significantly, primarily driven by higher research and development costs.

Solid Biosciences Inc. reported a net loss of $124.7 million for the year ended December 31, 2024, compared to $96.0 million in the previous year. The company's research and development expenses increased by $19.9 million, primarily due to increased manufacturing and study-related costs for SGT-501 and SGT-212. General and administrative expenses also rose by $5.5 million. The company anticipates continued operating losses and will require additional funding to support its development programs.

Solid Biosciences reported collaboration revenue of $6.2 million for the second quarter of 2022, compared to $3.6 million for the second quarter of 2021. Net loss for the second quarter of 2022 was $25.1 million, compared to $18.7 million for the second quarter of 2021. The company had $162.9 million in cash, cash equivalents and available-for-sale securities as of June 30, 2022.

Solid Biosciences announced an update to its strategic priorities to focus on developing SGT-001 and SGT-003. The company reported a net loss of $25.3 million for the first quarter of 2022 and had $180.1 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2022.

Solid Biosciences reported collaboration revenue of $3.6 million for the second quarter of 2021, driven by their collaboration agreement with Ultragenyx. The company's research and development expenses increased to $15.5 million, and they ended the quarter with approximately $249 million in cash and investments.

Solid Biosciences reported a net loss of $16.9 million for the first quarter of 2021. The company's cash and cash equivalents were $268.5 million as of March 31, 2021, expected to fund operations into Q4 2022. Patient 8 in the IGNITE DMD trial experienced a serious adverse event.

Solid Biosciences reported encouraging interim functional and biomarker data, and patient reported outcome measures (PROMs) from six patients after treatment in the ongoing IGNITE DMD Phase I/II clinical trial of its lead gene therapy candidate, SGT-001. The Company also announced that patient 7 in IGNITE DMD was safely dosed. The totality of data collected, and the re-initiation of dosing support the continued enrollment of patients into the IGNITE DMD study.

Solid Biosciences reported a net loss of $21.2 million for the third quarter of 2020. The company's cash and cash equivalents were $24.8 million as of September 30, 2020, which, combined with proceeds from Ultragenyx and ATM Sale, are expected to fund operations into the second half of 2021. The FDA lifted the clinical hold on the IGNITE DMD trial, with dosing expected to resume in the first quarter of 2021.

Solid Biosciences reported financial results for the fourth quarter and full year ending December 31, 2019. The company is focused on advancing its lead program, SGT-001, a gene therapy candidate for Duchenne muscular dystrophy and is working to address the IGNITE DMD clinical hold.